News
Xeljanz/Xeljanz XR Approved for Active Ankylosing Spondylitis
The approval was based on data from a phase 3 study which evaluated tofacitinib in adults with active AS who had an inadequate response to at least 2 NSAIDs.
Your search for tofacitinib returned 14 results
DDW 2022
Tofacitinib, Vedolizumab Effective for UC Post-Anti-TNF Agent Failure
Researchers compared the effectiveness of tofacitinib and vedolizumab among patients with UC who had experienced anti-TNF failure.
News
Tofacitinib vs TNFi for RA: Safety Study Results Announced
The randomized phase 3b/4 ORAL Surveillance study included 4362 RA patients who were taking methotrexate without adequate control of symptoms.
News
DMARDs Not Linked to Alzheimer Risk for Seniors With RA
No reduction in ADRD risk seen for treatment with tofacitinib, tocilizumab, TNF inhibitors versus abatacept
News
CV, Cancer Risk Up With Tofacitinib for Rheumatoid Arthritis
Incidences of major adverse cardiovascular events, cancers higher with tofacitinib versus TNF inhibitor; criteria for noninferiority not met
News
Xeljanz Approved for Active Polyarticular Course Juvenile Idiopathic Arthritis
Patients treated with tofacitinib experienced significantly fewer disease flares compared with placebo.
News
WHO Living Guideline Updated for Drug Treatment of COVID-19
JAK inhibitor baricitinib strongly recommended for the treatment of severe or critical COVID-19
Safety Alerts and Recalls
FDA: New Warnings and Limitations Set for Certain JAK Inhibitors
The revisions are based on a completed review of a large randomized safety clinical trial, which included 4362 patients with rheumatoid arthritis.
News
Rinvoq Labeling Updated to Include Class Warnings Related to JAK Inhibitors
The update follows the FDA’s Drug Safety Communication, which was based on a completed review of a large randomized safety clinical trial evaluating tofacitinib in patients with rheumatoid arthritis.
Drug Monograph Updates
December 2021 Recap of Drug Updates
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of December. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
